





Longevity swap markets – why just the UK?

Christopher Pigott – Munich Re Michael Walker – Aon Hewitt

Agenda

- 2 Is longevity risk universal?
- 3 Established markets
- 4 Challenges elsewhere?
- 5 Conclusions





Settlement across the world...


- Global longevity risk transfer* is dominated by UK transactions with UK pension schemes and UK insurers ceding risk to reinsurers...
- ...although in recent years there have been a number of notable deals in the US, Canada and the Netherlands, including...



^{*}Including both bulk annuities and longevity swaps




Drivers of a settlement market – pension scheme perspective





Global longevity exposure





Source: Aon Hewitt calculations based on data from OECD and EIOPA

Characteristics of an attractive market – reinsurer perspective



Whole of life income market

Existence of large pension funds

>US \$1 bn PV liabilities

Market ready to de-risk pensioners at an acceptable price

Evident longevity risk & mortality improvements

Drivers to de-risk


DB plans, regulatory requirements

Adequate data available to produce suitable basis






Mortality trends - UK




UK male vs female mortality rates (smoothed)





Source: Aon Hewitt calculations based on data from the Human Mortality Database.

International mortality trends




Source: Aon Hewitt calculations based on data from the Human Mortality Database.


Overall trend towards improvements in life expectancy, different levels of convergence between male and female life expectancies in different countries



Emerging mortality data – UK and Europe



Aon Hewitt calculations based on ONS data.



Charts show weekly national mortality for ages 65+ as deviations from a baseline allowing for trend and seasonality. Source: European monitoring of excess mortality for public health action http://www.euromomo.eu/outputs/zscore_country65.html

Institute and Faculty of Actuaries



The UK



Market

• Significant volume of transactions (deals covering >£50bn of liabilities) and massive opportunity:



Source: 'The Purple Book – DB Pensions Universe Risk Profile 2015' published by the Pension Protection Fund and The Pensions Regulator http://www.pensionprotectionfund.org.uk/DocumentLibrary/Documents/purple_book_2015.pdf

Basis

- Credible mortality experience data widely available
- Alignment of view between pension schemes and providers on base tables/improvements (i.e. SAPS / postcode models and CMI projection model)



The UK - evolution

Early market characteristics (pensions)

- Longevity swap transactions begin in 2009
 - Mainly £1bn+
 - Range of providers Credit Suisse, Rothesay Life, JP Morgan, Deutsche Bank / Abbey Life, Swiss Re, Legal & General, UBS,
 Nomura, ...
- Variety of contract structures
 - Insurance vs derivative
 - Index based vs indemnity (lives)
- Lengthy transaction times
 - Insurers and reinsurers becoming more familiar with DB pension structures (GMPs etc.)
 - Establishment of collateralisation approaches
 - Negotiation of terms and legal contracts



The UK - evolution

Recent themes (pensions)

- Standardisation
 - Indemnity only (lives)
 - Consistent collateral structures
 - Common legal terms
- Smaller transaction sizes
 - Pirelli £600m across two schemes (2016)
 - £50m and £90m undisclosed (2016 and 2015)
- Structures
 - Intermediated
 - Pass through
 - Captive
- Fewer participants
 - Legal & General, Zurich, ???

Recent themes (insurers)

- · Pension freedoms & Solvency II
 - Rapid decline of individual annuities
 - Increased volumes of bulk annuities
 - Risk Margin and capital requirements
 - Led to:
 - Sale of annuity back books
 - Reinsurance of longevity risk



The US



Market


- · Huge market for risk settlement
 - \$2tn of defined benefit pension liabilities
- Growing transaction volumes
- Typically pensioner transactions
 - Deferred (terminated vested) pensioners can be paid a lump sum on terms set by the IRS
 - Expect these terms to worsen in 2017 / 18

Basis

· Good data available for mortality base and trend

Opportunity

- Pension schemes transact bulk annuities not longevity swaps partly due to lack of indexation on most pensions in payment but also other drivers
- · For larger transactions longevity risk sometimes reinsured



Source: Year-end 2015, as reported in insurer responses to Aon Hewitt Investment Consulting's survey of the most significant U.S insurers.



The Netherlands



Market

- · Collective culture with large umbrella schemes currently held under insurers
- · Longevity risk transfer between insurers and reinsurers becoming more common

AEGON

Deutsche Bank

Basis

- · Good data available for mortality base and trend
- Differing views on life expectancy currently between pension schemes and reinsurers

Canada Life Reinsurance

Opportunity

- Potential for innovative longevity swap solutions for this market but regulator is cautious
- · Limited potential for pension schemes to undertake a longevity swap in current regime





The Netherlands



Regulation

- Q&A published by DNB in June 2016
- Covers index based vs indemnity based contracts
- For an index based swap, capital relief will be proportional to the risk transfer
 - Some previous index based deals the regulator has viewed as being too out-of-the-money
 - Regulators current view is that these deals are too short duration and not a good match for actual liabilities
- Different treatments on balance sheet:
 - Indemnity = reinsurance contract
 - Index = treated as financial instrument
- DNB assess longevity instruments on a case-by-case basis
- Much harder to now complete an index based swap




Canada



Market

- Bulk annuity deals have been ramping up over several years, but levels still low
- 2015 saw record de-risking transactions:
 - Largest bulk annuity deal of ~\$530m written by Sun Life
 - First longevity swap written covering ~\$5bn of liabilities (also with Sun Life)





Source: Aon, U.K and U.S. markets converted to \$CAD at August 26, 2016 exchange rate

Canada




Basis

- Canadian actuarial profession have released mortality tables (and are working on a new series)
- More insurers and reinsurers expected to enter the market and develop Canadian bases
- Pension schemes only tend to reassess mortality after periodic release of new studies

Opportunity

- Market already developing and expectations are for further growth, but at what rate?
- Change in pension scheme approach/cultural view to analysing longevity risk and mortality improvements







Challenges elsewhere?

Germany

· Occupational schemes written onto company balance sheet, no driver to de-risk

Australia

- · Generally not whole of life income upon retirement
- Often buy term annuities (20 years) at retirement then rely on the state
- Companies do not bear the risk

Japan

- · Low (or negative) mortality improvements worsening longevity
- No value perceived as being gained by longevity de-risking at the moment

Switzerland

• Incentivised to annuitise, but not forced – small market, but one that may open up in the future


South America and South Africa

- · Lack of historic data (not reliable or not collected at all)
 - Poor experience data
 - Hard to build a reliable basis





Select global markets





Conclusions

UK

- All characteristics of an attractive market are present
- Plenty of life left in the UK market, but currently constrained by human capacity, in future constrained by financial capacity

Other markets

- · We believe there could be attractive markets opening up in the future
 - Particularly Canada and the Netherlands
- Longevity swaps in the US unlikely under current regime
- Other markets could emerge
 - Regulation/cultural/economic changes may make new markets become attractive
- However, there are issues in a lot of markets that will be very hard to overcome from both the demand and supply sides of the market



Questions

Comments

The views expressed in this presentation are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this presentation and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this presentation.

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this presentation be reproduced without the written permission of the IFoA or authors.

